Midpoint Holdings Ltd.: Mr Derek Ivany Appointed to the Board

London, UK (April 14, 2021) - Midpoint Holdings Ltd. (TSXV: MPT) (“Midpoint” or the “Company”) is pleased to announce the following changes to its Board of Directors and Executive Officers:

-                      the appointment of Derek Ivany as a director, Chair of the Audit Committee, and Chair of Renumeration Committee of the Company;

-                      the resignation of Michael Hampson as a director of the Company.

The Company is pleased to welcome Mr. Ivany to its Board of Directors and as its Chair of Audit Committee, and Chair of Renumeration Committee.

Mr. Ivany most recently served as Chairman of the Midpoint Advisory board where he was instrumental in guiding the refinancing of the Company. In his new role as. Mr. Ivany will focus on expanding the Midpoint brand and business offerings with a particular emphasis on assessing strategic and synergistic opportunities within the burgeoning FinTech and Cryptocurrency arenas.

“I am very excited to focus my attention on guiding Midpoint as it embarks on the next phase of its growth trajectory,” stated Derek Ivany. He continued, “David Wong and his team have done an excellent job in building and maintaining a versatile payments platform that will serve as a strong base for future value enhancing opportunities. As a longstanding shareholder of Midpoint I very much look forward to working alongside the team with a view to enhancing corporate value to the benefit of all stakeholders. I believe Midpoint is well positioned to capitalize on industry tailwinds in the financial technology space.”

Mr. Ivany was previously the president and CEO of a publicly traded company that, during his tenure, expanded in valuation from $2-million in market capitalization to over $250-million at its zenith while generating significant investor liquidity along the way. Over the past year, he has spearheaded capital formation in excess of $15 million in various merchant banking mandates across the biotechnology, health and wellness, and technology sectors. Derek’s recent postings include his appointment to the Advisory Board of Relay Medical Corp. where he was instrumental in assisting with its growth financing, and as founder and director of Holy Crap Brands Inc. which was acquired by Plant & Co Brands Ltd. where he is now assisting in guiding corporate development and strategy. Additionally, Mr. Ivany served as founder and President of Pilz BioScience Corp., a biotechnology company developing medicinal psychedelics for neuroinflammatory conditions with the initial focus indication being Autism Spectrum Disorder. Pilz BioScience was subsequently acquired by Nova Mentis Life Science Corp.

In connection with Mr. Ivany’s appointment, David Wong, Midpoint’s CEO, stated “Derek brings a wealth of experience and an impressive track record. I look forward to working with Derek to deliver extraordinary appreciation of shareholder value. Like myself, Derek started of as a client of Midpoint, before becoming an investor and now joining the Midpoint team. This speaks volumes for the Midpoint proposition and company vision.”

The Company also wishes to thank Mr. Hampson for his valuable service to the Company. “It has been a pleasure to be part of the Midpoint team and to enjoy the journey over the years as we have expanded globally. I will continue to support the company as a client and shareholder as I focus on the next stage of Bishopsgate Financial my consulting business and other ventures that are in the pipeline. I would like to welcome and congratulate Mr. Derek Ivany on his appointment to the Board. I would also like to take this opportunity thank David for his dedication to Midpoint and the incredible work that he has done in turning this Company around, the results speak for itself. I look forward to following the continued success and growth of Midpoint in the coming years.” noted Mr. Hampson.

“It has been an incredible honor and pleasure to work with Mike. On behalf of Midpoint, we wish Mr. Hampson well for all his future endeavors and would welcome to opportunity to work together in future” said David Wong, CEO of Midpoint.

About Midpoint

Headquartered in London, UK, Midpoint is an FCA authorized payments institutions specializing in cross-border payments and foreign exchange. SMEs, overseas professionals, property owners, foreign students, individuals, and anyone involved in international payments use Midpoint’s US patent-protected platform for transparent, multi-party, multi-currency services.

Midpoint currently handles transactions in 26 currencies with the ability to collect and transfer across over 200 countries. This highly secure platform provides customers with the most cost-effective FX at the midpoint of the interbank buy/sell rate, therefore removing the spread as well as hidden costs and fees.

Midpoint Holdings Limited is listed on the TSX Venture Exchange and cross-listed on the Frankfurt Stock Exchange.

For further information, please contact:

Neither the TSX Venture Exchange (the “TSXV”) nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this news release.

Forward-looking information

This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. For a description of the risks and uncertainties facing Midpoint and its business and affairs, readers should refer to Midpoint’s Management’s Discussion and Analysis. Midpoint undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change, unless required by law. The reader is cautioned not to place undue reliance on forward-looking information.

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.